BioTuesdays

Category - Markets

Aurinia

Mackie starts Aurinia Pharma at speculative buy

Mackie Research launched coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a “speculative buy” recommendation and a 12-month target price of $8. The stock closed at $3.03 on Monday. Aurinia is developing...

Kindred Biosciences

Ladenburg starts Kindred Biosciences at buy

Ladenburg Thalmann initiated coverage of Kindred Biosciences (NASDAQ:KIN) with a “buy” rating and a $7.50 price target. The stock closed at $5.40 on Monday. “We view Kindred as an emerging leader in development of new...

RepliCel Life Sciences

Echelon ups RepliCel price target to $2.15

Echelon Wealth Partners raised its price target for RepliCel Life Sciences (TSX-V:RP) to $2.15 from $1.50 after the company closed a unit offering that will add about $4.1-million in net cash to its balance sheet. The...

Obalon Therapeutics

Analysts start Obalon Therapeutics at buy

Analysts at Stifel and BTIG initiated coverage of Obalon Therapeutics (NASDAQ:OBLN) with “buy” ratings and price targets of $18 and $20, respectively. The stock closed at $13.80 on Friday. “Obalon appears poised for...

Opexa Therapeutics

Maxim downgrades Opexa Therapeutics to hold

Maxim Group downgraded Opexa Therapeutics (NASDAQ:OPXA) to “hold” from “buy” and removed its previous price target of $18 after the company failed a Phase 2b trial in secondary progressive multiple sclerosis (SPMS). The...

AtriCure

Canaccord ups AtriCure price target to $23

Canaccord Genuity raised its price target for AtriCure (NASDAQ:ATRC) to $23 from $21 after the company reported third quarter results. The stock is trading at $17.74, up $2.54, at midday on Friday. The third quarter...

Agenus

HCW downgrades Agenus to neutral

H.C. Wainwright downgraded Agenus (NASDAQ:AGEN) to “neutral” from “buy” and slashed its price target to $5 from $10. The stock closed at $4.33 on Thursday. Analyst Swayampakula Ramakanth writes that during Agenus’ third...

CryoLife

Canaccord ups CryoLife price target to $23.50

Canaccord Genuity raised its price target for CryoLife (NYSE:CRY) to $23.50 from $17.50 after the company reported third quarter results. The stock is changing hands at $17.10 on Thursday afternoon. Analyst Jason Mills...

NeoGenomics

BTIG upgrades NeoGenomics to buy

BTIG upgraded NeoGenomics (NASDAQ:NEO) to “buy” from “neutral,” with a price target of $10, after the company reported third quarter results. The stock closed at $7.13 on Wednesday. “When we downgraded shares at $9, our...

Fulgent Genetics

BTIG starts Fulgent Genetics at buy

BTIG initiated coverage of Fulgent Genetics (NASDAQ:FLGT) with a ‘buy” rating and $15 price target. The stock closed at $8.86 on Friday. “While the genetic testing market is not without challenges and competition is...